Page last updated: 2024-08-17

quinoxalines and mdv 3100

quinoxalines has been researched along with mdv 3100 in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Dong, X; Feng, T; Gao, L; Han, B; Hu, J; Lu, Q; Sun, F; Wang, L; Wang, S; Wang, X; Xiong, X; Zhao, R; Zhou, Q1
Cashman, JR; Cheng, J; Gomez-Galeno, J; Lee, DH; Moore, S; Okolotowicz, KJ1

Other Studies

2 other study(ies) available for quinoxalines and mdv 3100

ArticleYear
TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
    Oncogene, 2020, Volume: 39, Issue:2

    Topics: Animals; Benzamides; Cell Proliferation; Disease Progression; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Male; Mice; Nitriles; Oxidative Stress; Peroxiredoxins; Phenylthiohydantoin; Prostate; Prostatic Neoplasms, Castration-Resistant; Protein Stability; Proto-Oncogene Proteins c-mdm2; Quinoxalines; Reactive Oxygen Species; Receptors, Androgen; Signal Transduction; Thioredoxins

2020
A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer.
    The Journal of pharmacology and experimental therapeutics, 2019, Volume: 371, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Benzamides; Cell Line, Tumor; Drug Synergism; Humans; Male; Mice; Nitriles; Phenylthiohydantoin; Piperazines; Prostatic Neoplasms; Quinoxalines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2019